Efficacy and Safety of Ubrogepant and Rimegepant in the Treatment of Acute Migraine :A Meta-analysis
- VernacularTitle:Ubrogepant和Rimegepant治疗急性期偏头痛疗效与安全性的Meta分析
- Author:
Xin LIU
1
;
Xiaoyan ZHONG
2
;
Changjing XU
1
,
2
;
Liya FU
1
;
Dongmei TIAN
1
;
Bin YU
3
;
Yilan HUANG
2
Author Information
1. School of Pharmacy,Southwest Medical University,Sichuan Luzhou 646000,China
2. Dept. of Pharmacy,the Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China
3. Dept. of Pharmacy,Mianyang Central Hospital,Sichuan Mianya ng 621000,China
- Publication Type:Journal Article
- Keywords:
Calcitonin gene-related peptide receptor antagonists;
Ubrogepant;
Rimegepant;
Acute migraine;
Efficacy;
Safety
- From:
China Pharmacy
2020;31(16):2017-2022
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systemat ically evaluate the efficacy and safety of Ubrogepant and Rimegepant in the treatment of acute migraine ,and to provide evidence-based reference for the clinical treatment. METHODS :Retrieved from PubMed ,Embase, Cochrane Library ,CNKI,VIP,Wanfang database and Clinicaltrials. gov ,randomized controlled trials (RCTs) about the Ubrogepant and Rimegepant (trial group )versus placebo (control group )in the treatment of acute migraine were collected during the inception to Jan. 2020. After literature screening and data extraction ,quality assessment was performed using the bias risk assessment tool provided by the Cochrane system evaluator manual 5.1.0. Meta-analysis was performed by using Stata 16.0 software. RESULTS :Eight RCTs with a total of 7 989 patients were included. The results of Meta-analysis showed that the proportion of patients who were free from pain at 2 h postdose in Ubrogepant group [RR =1.65,95%CI(1.38,1.98),P<0.001] and Rimegepant group [RR =1.69,95%CI(1.46,1.95),P<0.001],the proportion of patients who were free from the most bothersome symptom at 2 h postdose in Ubrogepant group [RR =1.35,95% CI(1.20,1.53),P<0.001] and Rimegepant group [RR =1.37,95%CI(1.24,1.51),P<0.001],and other secondary outcome indicators ( i.e. the proportion of patients with pain relief at 2 h postdose ,the proportion of patients with sustained freedom from pain from 2-24 h postdose ,the proportion of patients with sustained pain relief from 2-24 h postdose ,the proportion of patients without photophobia at 2 h postdose ,the proportion of patients without phonophobia at 2 h postdose ,the proportion of patients without nausea at 2 h postdose )were all significantly better than control group (P<0.05). In terms of safety ,there was no statistical significance in the incidence of total ADR between Ubrogepant group and control group [RR =1.04,95%CI(0.87,1.25),P=0.646],but the incidence of total ADR in Rimegepant group were significantly higher than control group [RR =1.23,95% CI(1.01,1.50),P=0.043]. There was no statistical significance in other security indicators (i.e. incidence of nausea ,dizziness,dry mouth ,somnolence,urinary tract infection)in 2 groups(P>0.05). CONCLUSIONS :Ubrogepant and Rimegepant are effective in the treatment of acute migraine. Ubrogepant is safe ,while Rimegepant may increase the incidence of ADR.